OSURHealthcare · Medical Instruments & SuppliesOSUR Stock Forecast: OraSure Technologies, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering OraSure Technologies, Inc. hold a median 12-month price target of $4 — -3.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 1 Aug 2026 — in the upper half. The factors read stronger than the Street's target implies. That gap is the story on this page.
OSUR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores OraSure Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (80): The share price has been relatively steady.
Quality (35): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own OraSure Technologies, Inc. — and when they’d sell — is the membership.
OSUR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OSUR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −3.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Nov 2025 | Stephens & Co. | Maintains | Equal-Weight | $3.50 → $3.00 |
| 19 May 2025 | Evercore ISI Group | Maintains | In-Line | — |
| 8 May 2025 | Evercore ISI Group | Maintains | In-Line | — |
| 7 Aug 2024 | Evercore ISI Group | Maintains | In-Line | — |
| 2 July 2024 | Evercore ISI Group | Maintains | In-Line | — |
| 13 May 2024 | JP Morgan | Maintains | Neutral | — |
| 4 Apr 2024 | Evercore ISI Group | Maintains | In-Line | — |
| 29 Feb 2024 | JP Morgan | Maintains | Neutral | — |
| 11 Dec 2023 | Citigroup | Maintains | Buy | — |
| 8 Nov 2023 | JP Morgan | Maintains | Neutral | — |
| 17 July 2023 | Stephens & Co. | Maintains | Equal-Weight | — |
| 11 May 2022 | Citigroup | Maintains | Buy | — |
| 24 Feb 2022 | Citigroup | Maintains | Buy | — |
| 22 Sept 2021 | Raymond James | Downgrade | Market Perform | — |
| 4 Aug 2021 | Raymond James | Maintains | Outperform | — |
| 28 June 2021 | Raymond James | Maintains | Outperform | — |
| 6 May 2021 | Raymond James | Maintains | Outperform | — |
| 21 Aug 2020 | Evercore ISI Group | Initiates | Outperform | — |
| 10 Aug 2020 | Citigroup | Initiates | Buy | — |
| 10 Aug 2020 | JP Morgan | Initiates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OSUR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
OraSure Technologies, Inc. (OSUR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 19.9×
- Price / sales
- 2.5×
- Price / book
- 0.9×
- EV / EBITDA
- −1.9×
Cheaper than 39% of US stocks
Cheaper than 47% of US stocks
Cheaper than 75% of US stocks
Cheaper than 71% of US stocks
- Revenue growth (YoY)
- −6.7%
- Earnings growth (YoY)
- —
- Gross margin
- 42.3%
- Operating margin
- −78.4%
- Net margin
- −66.4%
Higher than 19% of US stocks
Higher than 54% of US stocks
Higher than 15% of US stocks
Higher than 8% of US stocks
- Return on equity
- −21.2%
- Return on assets
- −10.6%
- Dividend yield
- —
Higher than 30% of US stocks
Higher than 26% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
OSUR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OSUR appears on the weeks it earns a place.
Frequently asked questions about OSUR stock
What is the OSUR stock price forecast for 2026-2027?
The 1 Wall Street analysts covering OraSure Technologies, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OSUR stock a buy right now?
Of the 1 analysts covering OraSure Technologies, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OraSure Technologies, Inc. 73 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OSUR?
As at 1 Aug 2026, OraSure Technologies, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (80 of 100).
Will OSUR stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies -3.8% from the last close, and Ticker Nerd's factor model ranks OraSure Technologies, Inc. 73 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OSUR stock forecast for 2030?
No analyst covering OraSure Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSUR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.
How has OSUR stock performed over the past year?
OraSure Technologies, Inc. returned +38.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does OraSure Technologies, Inc. do?
Orasure Technologies Inc. is a biotechnology company primarily focused on developing point-of-care diagnostic testing and specimen collection devices.
About OraSure Technologies, Inc.
Orasure Technologies Inc. is a biotechnology company primarily focused on developing point-of-care diagnostic testing and specimen collection devices. Known for its innovation in oral fluid diagnostics, Orasure provides critical solutions in the healthcare sector. Their product portfolio includes diagnostic tests for infectious diseases, such as HIV and Hepatitis C, leveraging easy-to-use, rapid results that are essential for timely medical interventions. Additionally, Orasure offers services and tools for the life sciences, including molecular sample collection and stabilization products utilized in genetic and microbiome research. The company's products serve a diverse range of sectors, including hospitals, clinics, and public health organizations, contributing significantly to both disease prevention and management. Headquartered in Bethlehem, Pennsylvania, Orasure Technologies plays a pivotal role in advancing public health infrastructure by offering reliable, user-friendly diagnostic tools that empower healthcare providers and patients alike. In the broader market context, Orasure addresses the growing demand for at-home and rapid testing solutions, which have become increasingly crucial components of modern healthcare systems worldwide.
CEO Ms. Carrie Eglinton Manner · 500 employees · United States · https://www.orasure.com